Genfit S.A. (EPA:GNFT – Get Free Report) traded up 0.7% on Thursday . The stock traded as high as €3.50 ($3.57) and last traded at €3.50 ($3.57). 145,395 shares traded hands during mid-day trading, The stock had previously closed at €3.47 ($3.54).
Genfit Price Performance
The company’s 50 day moving average is €3.96 and its two-hundred day moving average is €4.17.
About Genfit
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Featured Articles
- Five stocks we like better than Genfit
- Using the MarketBeat Dividend Yield Calculator
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- How to Capture the Benefits of Dividend Increases
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- The Role Economic Reports Play in a Successful Investment Strategy
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
